243 related articles for article (PubMed ID: 30741673)
1. Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability.
Takamatsu Y; Ho G; Waragai M; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M
J Alzheimers Dis; 2019; 68(2):473-481. PubMed ID: 30741673
[TBL] [Abstract][Full Text] [Related]
2. Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability.
Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Waragai M; Masliah E; Takenouchi T
Prion; 2020 Dec; 14(1):1-8. PubMed ID: 32375593
[TBL] [Abstract][Full Text] [Related]
3. Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease.
Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Waragai M; Masliah E
J Parkinsons Dis; 2019; 9(4):793-802. PubMed ID: 31524179
[TBL] [Abstract][Full Text] [Related]
4. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability.
Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Waragai M
J Huntingtons Dis; 2018; 7(4):297-307. PubMed ID: 30372687
[TBL] [Abstract][Full Text] [Related]
5. Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates.
Hashimoto M; Ho G; Takamatsu Y; Shimizu Y; Sugama S; Takenouchi T; Waragai M; Masliah E
J Parkinsons Dis; 2018; 8(3):405-408. PubMed ID: 30010144
[TBL] [Abstract][Full Text] [Related]
6. Connecting Alzheimer's Disease With Diabetes Mellitus Through Amyloidogenic Evolvability.
Ho G; Takamatsu Y; Wada R; Sugama S; Waragai M; Takenouchi T; Masliah E; Hashimoto M
Front Aging Neurosci; 2020; 12():576192. PubMed ID: 33192467
[TBL] [Abstract][Full Text] [Related]
7. Evolvability of Amyloidogenic Proteins in Human Brain.
Hashimoto M; Ho G; Sugama S; Takamatsu Y; Shimizu Y; Takenouchi T; Waragai M; Masliah E
J Alzheimers Dis; 2018; 62(1):73-83. PubMed ID: 29439348
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?
Waragai M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M
Front Endocrinol (Lausanne); 2020; 11():108. PubMed ID: 32194507
[TBL] [Abstract][Full Text] [Related]
9. Motor and Nonmotor Symptoms of Parkinson's Disease: Antagonistic Pleiotropy Phenomena Derived from
Takamatsu Y; Fujita M; Ho GJ; Wada R; Sugama S; Takenouchi T; Waragai M; Masliah E; Hashimoto M
Parkinsons Dis; 2018; 2018():5789424. PubMed ID: 30595837
[TBL] [Abstract][Full Text] [Related]
10. Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy.
Wei J; Ho G; Masliah E; Hashimoto M
Prion; 2023 Dec; 17(1):29-34. PubMed ID: 36785484
[TBL] [Abstract][Full Text] [Related]
11. Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer's Disease.
Hashimoto M; Ho G; Sugama S; Takenouchi T; Waragai M; Sugino H; Inoue S; Masliah E
J Alzheimers Dis; 2021; 81(2):451-458. PubMed ID: 33814453
[TBL] [Abstract][Full Text] [Related]
12. Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.
Chung JK; Nakajima S; Plitman E; Iwata Y; Uy D; Gerretsen P; Caravaggio F; Chakravarty MM; Graff-Guerrero A
Am J Geriatr Psychiatry; 2016 Oct; 24(10):923-39. PubMed ID: 27526990
[TBL] [Abstract][Full Text] [Related]
13. Network-based analysis on the genes and their interactions reveals link between schizophrenia and Alzheimer's disease.
Guo P; Meng C; Zhang S; Cai Y; Huang J; Shu J; Wang J; Cai C
Neuropharmacology; 2024 Feb; 244():109802. PubMed ID: 38043643
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin paradox as a therapeutic target of the cancer evolvability in aging.
Takamatsu Y; Ho G; Wada R; Inoue S; Hashimoto M
Neoplasia; 2021 Jan; 23(1):112-117. PubMed ID: 33310207
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease.
Waragai M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M
J Alzheimers Dis; 2020; 76(4):1249-1253. PubMed ID: 32623396
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
17. Analysis of mRNA and Protein Levels of
Di Maio A; De Rosa A; Pelucchi S; Garofalo M; Marciano B; Nuzzo T; Gardoni F; Isidori AM; Di Luca M; Errico F; De Bartolomeis A; Marcello E; Usiello A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163460
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
Mullane K; Williams M
Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease.
Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T
Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165
[TBL] [Abstract][Full Text] [Related]
20. Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic Evolvability.
Ho G; Choo PC; Waragai M; Inoue S; Masliah E; Hashimoto M
J Alzheimers Dis Rep; 2022; 6(1):207-210. PubMed ID: 35591950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
